Read more

September 26, 2019
1 min read
Save

Schwind launches laser platform for femtoLASIK and lenticule extraction

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Thomas Wendler

PARIS — At the European Society of Cataract and Refractive Surgeons meeting, Schwind eye-tech-solutions launched the ATOS femtosecond laser, with capabilities for both femtoLASIK and innovative lenticule extraction with the SmartSight technology.

This new laser features intelligent eye tracking with pupil recognition and cyclotorsion compensation for precise centration of the eye on the visual axis. The curved shape of the patient interface ergonomically adapts to the cornea, reducing pressure on the eye.

“As a company leader in refractive surgery, we strive for perfection, and this new product confirms the highest standards of our technologies for smooth corneal surfaces. Both the lenticule extraction and LASIK flaps made with the Schwind ATOS exhibit high homogeneity and perfect smoothness, leading to fast visual recovery,” Thomas Wendler, head of research and development at Schwind, said in an interview with Healio.com/OSN.

The small, almost mobile design is flexible to use in today’s clinical practice, he said. “It is a very user-friendly machine, allowing for clear, intuitive planning and efficient workflow.”

Kishore Pradhan

First results of myopic SmartSight in 34 eyes performed in India by Rohit Shetty, MD, and in Switzerland by Theo Seiler, MD, PhD, showed high quality of the incision and lenticule, fast recovery and excellent visual outcomes. Nearly 90% of the eyes achieved 20/20 on day 1 and are stable at 6 months.

A study is also underway in Nepal.

“According to my first experiences with the Schwind ATOS, the system is safe and accurate, and the lenticule can be easily removed. We will soon start an investigation with 150 eyes in our clinic, and I expect very good patient outcomes,” said Kishore Pradhan, MD, of Matrika Eye Center in Kathmandu, Nepal. by Michela Cimberle

Disclosure: Wendler reports he is head of research and development at Schwind eye-tech-solutions. Pradhan reports no relevant financial disclosures.